Literature DB >> 25461734

Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis.

Alexandra V Potekhina1, Ekaterina Pylaeva2, Sergey Provatorov3, Natalya Ruleva4, Valery Masenko5, Elena Noeva6, Tatiana Krasnikova7, Tatiana Arefieva8.   

Abstract

Objective. Immune processes play a significant role in atherosclerosis plaque progression. Regulatory T cells and T helpers 17 were shown to possess anti- and pro-atherogenic activity, respectively. We aimed to investigate the balance of circulating Treg and Th17 in stable angina patients with different stages of coronary atherosclerosis. Methods. Treg, Th17 and Th1 cell frequencies were studied in 117 patients via direct immunofluorescence staining and flow cytometry. Group 1 had intact coronary arteries. Group 2 and Group 3 had undergone previous coronary stenting; in Group 2 no coronary atherosclerosis progression was found, in Group 3 patients had disease progression in non-invaded coronary arteries. Group 4 had severe coronary atherosclerosis. Results. The frequencies of CD4+CD25highCD127low, CD4+foxp3+, and CD4+IL10 + T cells were decreased, and CD4+IL17 + T cells frequencies were increased in group 4 vs. 1. Treg/Th17 ratios were declined in groups 3 and 4 vs. groups 1 and 2. IL-10 level was lower while hsCRP and sCD25 levels were higher in group 4 vs. 1. Conclusion. We assume that the imbalance in pro- and anti-inflammatory/atherogenic lymphocyte subpopulations is associated with atherosclerosis progression.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Coronary artery disease; Regulatory T cells; T helpers 17

Mesh:

Substances:

Year:  2014        PMID: 25461734     DOI: 10.1016/j.atherosclerosis.2014.10.088

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  33 in total

1.  The reduced soluble fibrinogen-like protein 2 and regulatory T cells in acute coronary syndrome.

Authors:  Kun Liu; Ting Li; Shiyuan Huang; Rui Long; Ya You; Jinping Liu; Zhaohui Wang
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-28

Review 2.  Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.

Authors:  Charlotte Spitz; Holger Winkels; Christina Bürger; Christian Weber; Esther Lutgens; Göran K Hansson; Norbert Gerdes
Journal:  Cell Mol Life Sci       Date:  2015-10-30       Impact factor: 9.261

Review 3.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

4.  miR-19a mitigates hypoxia/reoxygenation-induced injury by depressing CCL20 and inactivating MAPK pathway in human embryonic cardiomyocytes.

Authors:  Qiang Fu; Tao-Ran Mo; Xiao-Yang Hu; Yin Fu; Ji Li
Journal:  Biotechnol Lett       Date:  2020-11-09       Impact factor: 2.461

Review 5.  ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.

Authors:  Klaus Ley; Norbert Gerdes; Holger Winkels
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-30       Impact factor: 8.311

6.  Differential expression of T cell-related genes in AMI and SA stages of coronary artery disease.

Authors:  Wenwen Yan; Lemin Wang; Jinfa Jiang; Wenjun Xu; Zhu Gong; Qianglin Duan; Chuanrong Li; Haoming Song; Lin Che; Yuqin Shen; Lin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Upregulation of OLR1 and IL17A genes and their association with blood glucose and lipid levels in femoropopliteal artery disease.

Authors:  Caner Arslan; Burcu Bayoglu; Cigdem Tel; Mujgan Cengiz; Ahmet Dirican; Kazim Besirli
Journal:  Exp Ther Med       Date:  2017-01-24       Impact factor: 2.447

8.  New insights into immunomodulation via overexpressing lipoic acid synthase as a therapeutic potential to reduce atherosclerosis.

Authors:  Shaomin Tian; Jun Nakamura; Sylvia Hiller; Stephen Simington; Darcy W Holley; Roberto Mota; Monte S Willis; Scott J Bultman; J Christopher Luft; Joseph M DeSimone; Zhenquan Jia; Nobuyo Maeda; Xianwen Yi
Journal:  Vascul Pharmacol       Date:  2020-08-01       Impact factor: 5.773

9.  Interleukin-22, a potent target for treatment of non-autoimmune diseases.

Authors:  Yue Zheng; Tong Li
Journal:  Hum Vaccin Immunother       Date:  2018-10-31       Impact factor: 3.452

10.  Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease.

Authors:  Saranya Ravi; Robert N Schuck; Eleanor Hilliard; Craig R Lee; Xuming Dai; Kaitlin Lenhart; Monte S Willis; Brian C Jensen; George A Stouffer; Cam Patterson; Jonathan C Schisler
Journal:  Am J Pathol       Date:  2017-11-16       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.